市場調査レポート
商品コード
1096357

血液悪性腫瘍検査の世界市場 (2022-2032年):検査製品・用途・国別の分析・予測・サプライチェーン分析

Global Hematologic Malignancies Testing Market: Focus on Hematologic Malignancies Testing Product and Application, Supply Chain Analysis, and Country Analysis - Analysis and Forecast, 2022-2032

出版日: | 発行: BIS Research | ページ情報: 英文 278 Pages | 納期: 1~5営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=152.41円
血液悪性腫瘍検査の世界市場 (2022-2032年):検査製品・用途・国別の分析・予測・サプライチェーン分析
出版日: 2022年06月28日
発行: BIS Research
ページ情報: 英文 278 Pages
納期: 1~5営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の血液悪性腫瘍検査の市場規模は、2021年の26億650万米ドルから、予測期間中は14.23%のCAGRで推移し、2032年には116億8,010万米ドルの規模に成長すると予測されています。

多数のバイオマーカーに基づく分子診断への需要が高まっており、同市場の成長を推進しています。また、先進国および新興国における精密診断技術の認知度および採用の向上も同市場の成長を牽引しています。

当レポートでは、世界の血液悪性腫瘍検査の市場を調査し、市場概要、市場成長への各種影響因子の分析、市場規模の推移・予測、各種区分・地域/主要国別の内訳、競合環境、主要企業のプロファイルなどをまとめています。

目次

第1章 市場

  • 製品の定義
  • 市場範囲
  • 市場概要

第2章 市場力学

  • 概要
  • 影響分析
  • 市場促進要因
  • 市場抑制要因
  • 市場機会
  • 産業分析
  • COVID-19:癌診断市場への影響
  • サプライチェーン分析
  • 価格分析
  • 血液悪性腫瘍検査の比較分析:各種パラメータ別

第3章 競合情勢

  • 概要
  • 相乗効果のある活動
  • 製品の発売
  • 製品の承認
  • M&A
  • その他の事業活動
  • 市場シェア分析 (企業別)
  • 成長シェア分析 (プラットフォーム別)

第4章 製品

  • キット
  • サービス

第5章 プラットフォーム

  • 次世代シーケンシング (NGS)
  • ポリメラーゼ連鎖反応 (PCR)
  • 蛍光insituハイブリダイゼーション (FISH)
  • 免疫組織化学 (IHC)
  • フローサイトメトリー
  • その他

第6章 疾患

  • 概要
  • 白血病
  • リンパ腫
  • 多発性骨髄腫
  • 骨髄増殖性腫瘍
  • 骨髄異形成症候群

第7章 エンドユーザー

  • 概要
  • 専門クリニック・病院
  • 診断ラボ
  • リファレンスラボ
  • 研究機関

第8章 地域

  • 概要
  • 北米
  • 欧州
  • アジア太平洋
  • ラテンアメリカ
  • その他の地域

第9章 市場:企業プロファイル

  • 概要
  • Abbott.
  • ASURAGEN, INC.
  • Adaptive Biotechnologies
  • ARUP Laboratories
  • Bio-Rad Laboratories, Inc.
  • F. Hoffmann-La Roche Ltd
  • Illumina, Inc.
  • ICON plc
  • Invivoscribe, Inc.
  • Invitae Corporation.
  • Laboratory Corporation of America Holdings
  • NeoGenomics Laboratories
  • OHSU's Knight Diagnostic Laboratories
  • Precipio
  • QIAGEN N.V.
  • Quest Diagnostics
  • Sysmex Corporation
図表

List of Figures

  • Figure 1: Estimated Hematologic Malignancies Cases
  • Figure 2: Impact Analysis of Market Drivers and Market Challenges on the Global Hematologic Malignancies Testing Market
  • Figure 3: Global Hematologic Malignancies Testing Market (by Product), $Million, 2021 and 2032
  • Figure 4: Global Hematologic Malignancies Testing Market (by Platform), $Million, 2021 and 2032
  • Figure 5: Global Hematologic Malignancies Testing Market (by Disease), $Million, 2021 and 2032
  • Figure 6: Global Hematologic Malignancies Testing Market (by End User), $Million, 2021 and 2032
  • Figure 7: Global Hematologic Malignancies Testing Market
  • Figure 8: Global Hematologic Malignancies Testing Market: Research Methodology
  • Figure 9: Primary Research Methodology
  • Figure 10: Bottom-Up Approach (Segment-Wise Analysis)
  • Figure 11: Global Hematologic Malignancies Testing Market Segmentation
  • Figure 12: Classification of Hematologic Malignancies
  • Figure 13: Global Hematologic Malignancies Testing Market, $Million, 2021-2032
  • Figure 14: Blood Cancer Cases, 2021 (% Share)
  • Figure 15: Workflow for the Product Approval in the Market
  • Figure 16: Workflow for the IVD Product Approval
  • Figure 17: Workflow for Medical Device Regulations
  • Figure 18: Workflow for Market Approval of In-Vitro Diagnostics in China
  • Figure 19: COVID-19 Poses Several Concerns for Patients, Health Care Providers, and Health Systems
  • Figure 20: Global Hematologic Malignancies Testing Market: COVID-19 Impact Analysis
  • Figure 21: Medical Research Cycle Interruption during the COVID-19 Pandemic
  • Figure 22: Telemedicine's Potential Advantages
  • Figure 23: Hematologic Malignancies Testing Supply Chain Analysis
  • Figure 24: Share of Key Developments and Strategies, January 2018-May 2022
  • Figure 25: Share of Synergistic Activities (by Company), January 2018-May 2022
  • Figure 26: Number of Product Launches (by Company), January 2018-May 2022
  • Figure 27: Share of Product Approval (by Company), January 2018-May 2022
  • Figure 28: Share of Mergers and Acquisitions (by Company), January 2018-May 2022
  • Figure 29: Share of other business activities (by Company), January 2018-May 2022
  • Figure 30: Market Share Analysis of Global Hematologic Malignancies Testing Market (by Company), 2020 and 2021
  • Figure 31: Growth-Share Analysis for Global Hematologic Malignancies Testing Market (by Platform), 2021
  • Figure 32: Segmentation of Hematologic Malignancies Testing Market
  • Figure 33: Share of Global Hematologic Malignancies Market (by Product), $Million, 2021 and 2032
  • Figure 34: Global Hematologic Malignancies Testing Market (by Kits)
  • Figure 35: Global Hematologic Malignancies Testing Market (Kits), $Million, 2021-2032
  • Figure 36: Global Hematologic Malignancies Testing Market (Kits), Thousand Units, 2021-2032
  • Figure 37: Global Hematologic Malignancies Testing Market (Gene Panels), $Million, 2021-2032
  • Figure 38: Global Hematologic Malignancies Testing Market (Gene Panels), Thousand Units, 2021-2032
  • Figure 39: Global Hematologic Malignancies Testing Market (Molecular Clonality Testing), $Million, 2021-2032
  • Figure 40: Global Hematologic Malignancies Testing Market (Molecular Clonality Testing), Thousand Units, 2021-2032
  • Figure 41: Company Offering Translocation Panel for Leukemia
  • Figure 42: Global Hematologic Malignancies Testing Market (Translocation Testing), $Million, 2021-2032
  • Figure 43: Global Hematologic Malignancies Testing Market (Translocation Testing), Thousand Units, 2021-2032
  • Figure 44: Companies Offering Mutation Testing Kits
  • Figure 45: Global Hematologic Malignancies Testing Market (Mutation Testing), $Million, 2021-2032
  • Figure 46: Global Hematologic Malignancies Testing Market (Mutation testing), Thousand Units, 2021-2032
  • Figure 47: Global Hematologic Malignancies Testing Market (Minimal Residual Disease (MRD) Testing), $Million, 2021-2032
  • Figure 48: Global Hematologic Malignancies Testing Market (Minimal Residual Disease (MRD) Testing), Thousand Units, 2021-2032
  • Figure 49: Global Hematologic Malignancies Testing Market (Services), $Million, 2021-2032
  • Figure 50: Global Hematologic Malignancies Testing Market (Services), Thousand Units, 2021-2032
  • Figure 51: Global Hematologic Malignancies Testing Market (by Platform)
  • Figure 52: Share of Global Hematologic Malignancies Testing Market (by Platform), $Million, 2021 and 2032
  • Figure 53: Benefits of NGS for Clinical Diagnostics and Biomarker Testing in Oncology
  • Figure 54: Global Hematologic Malignancies Testing Market (Next-Generation Sequencing (NGS)), $Million, 2021-2032
  • Figure 55: Global Hematologic Malignancies Testing Market (Next-Generation Sequencing), Thousand Units, 2021-2032
  • Figure 56: Global Hematologic Malignancies Testing Market (Polymerase Chain Reaction (PCR)), $Million, 2021-2032
  • Figure 57: Global Hematologic Malignancies Testing Market (Polymerase Chain Reaction (PCR)), Thousand Units, 2021-2032
  • Figure 58: Global Hematologic Malignancies Testing Market (Fluorescence In-Situ Hybridization (FISH)), $Million, 2021-2032
  • Figure 59: Global Hematologic Malignancies Testing Market (Fluorescence In-Situ Hybridization (FISH)), Thousand Units, 2021-2032
  • Figure 60: Global Hematologic Malignancies Testing Market (Immunohistochemistry (IHC)), $Million, 2021-2032
  • Figure 61: Global hematologic malignancies testing Market (Immunohistochemistry), Thousand Units, 2021-2032
  • Figure 62: Global Hematologic Malignancies Testing Market (Flow Cytometry), $Million, 2021-2032
  • Figure 63: Global Hematologic Malignancies Testing Market (Flow Cytometry), Thousand Units, 2021-2032
  • Figure 64: Global Hematologic Malignancies Testing Market (Other Platforms), $Million, 2021-2032
  • Figure 65: Global Hematologic Malignancies Testing Market (Other Platforms), Thousand Units, 2021-2032
  • Figure 66: Share of Global Hematologic Malignancies Testing Market (by Disease), $Million, 2021 and 2032
  • Figure 67: Global Hematologic Malignancies Testing Market (Leukemia), $Million, 2021-2032
  • Figure 68: Global Hematologic Malignancies Testing Market (Lymphoma), $Million, 2021-2032
  • Figure 69: Global Hematologic Malignancies Testing Market (Multiple Myeloma), $Million, 2021-2032
  • Figure 70: Global Hematologic Malignancies Testing Market (Myeloproliferative Neoplasms), $Million, 2021-2032
  • Figure 71: Global Hematologic Malignancies Testing Market (Myelodysplastic Syndromes), $Million, 2021-2032
  • Figure 72: Share of Global Hematologic Malignancies Testing Market (by End User), $Million, 2021 and 2032
  • Figure 73: Global Hematologic Malignancies Testing Market (Specialty Clinics and Hospitals), $Million, 2021-2032
  • Figure 74: Global Hematologic Malignancies Testing Market (Specialty Clinics and Hospitals), Thousand Units, 2021-2032
  • Figure 75: Global Hematologic Malignancies Testing Market (Diagnostic Laboratories), $Million, 2021-2032
  • Figure 76: Global Hematologic Malignancies Testing Market (Diagnostic Laboratories), Thousand Units, 2021-2032
  • Figure 77: Global Hematologic Malignancies Testing Market (Reference Laboratories), $Million, 2021-2032
  • Figure 78: Global Hematologic Malignancies Testing Market (Reference Laboratories), Thousand Units, 2021-2032
  • Figure 79: Global Hematologic Malignancies Testing Market (Research Institutions), $Million, 2021-2032
  • Figure 80: Global Hematologic Malignancies Testing Market (Research Institutions), Thousand Units, 2021-2032
  • Figure 81: Global Hematologic Malignancies Testing Market Snapshot (by Region), $Million, 2021-2032
  • Figure 82: Global Hematologic Malignancies Testing Market (by Region), $Million, 2021-2032
  • Figure 83: North America Hematologic Malignancies Testing Market, $Million, 2021-2032
  • Figure 84: North America: Market Dynamics
  • Figure 85: North America Hematologic Malignancies Testing Market (by Country), $Million, 2021-2032
  • Figure 86: North America Hematologic Malignancies Testing Market, Thousand Units, 2022-2032
  • Figure 87: U.S. Hematologic Malignancies Testing Market, $Million, 2021-2032
  • Figure 88: U.S. Hematologic Malignancies Testing Market, Thousand Units, 2021-2032
  • Figure 89: U.S. Hematologic Malignancies Testing Market (by Platform), $Million, 2021-2032
  • Figure 90: U.S. Hematologic Malignancies Testing Market (by Platform), Thousand Units, 2021, 2025, and 2032
  • Figure 91: U.S. Hematologic Malignancies Testing Market (by Product), Thousand Units, 2021, 2025, and 2032
  • Figure 92: U.S. Hematologic Malignancies Testing Market (by End User), Thousand Units, 2021, 2025, and 2032
  • Figure 93: Canada Hematologic Malignancies Testing Market, $Million, 2021-2032
  • Figure 94: Canada Hematologic Malignancies Testing Market, Thousand Units, 2021-2032
  • Figure 95: Canada Hematologic Malignancies Testing Market (by Platform), $Million, 2021-2032
  • Figure 96: Canada Hematologic Malignancies Testing Market (by Platform), Thousand Units, 2021, 2025, and 2032
  • Figure 97: Canada Hematologic Malignancies Testing Market (by Product), Thousand Units, 2021, 2025, and 2032
  • Figure 98: Canada Hematologic Malignancies Testing Market (by End User), Thousand Units, 2021, 2025, and 2032
  • Figure 99: Europe Hematologic Malignancies Testing Market, $Million, 2021-2032
  • Figure 100: Europe Hematologic Malignancies Testing Market (by Country), $Million, 2021-2032
  • Figure 101: Europe: Market Dynamics
  • Figure 102: Europe Hematologic Malignancies Testing Market, Thousand Units, 2021-2032
  • Figure 103: Germany Hematologic Malignancies Testing Market, $Million, 2021-2032
  • Figure 104: Germany Hematologic Malignancies Testing Market, Thousand Units, 2021-2032
  • Figure 105: Germany Hematologic Malignancies Testing Market (by Platform), $Million, 2021-2032
  • Figure 106: Germany Hematologic Malignancies Testing Market (by Platforms), Thousand Units, 2021, 2025, and 2032
  • Figure 107: Germany Hematologic Malignancies Testing Market (by Product), Thousand Units, 2021, 2025, and 2032
  • Figure 108: Germany Hematologic Malignancies Testing Market (by End User), Thousand Units, 2021, 2025, and 2032
  • Figure 109: France Hematologic Malignancies Testing Market, $Million, 2021-2032
  • Figure 110: France Hematologic Malignancies Testing Market, Thousand Units, 2021-2032
  • Figure 111: France Hematologic Malignancies Testing Market (by Platform), $Million, 2021-2032
  • Figure 112: France Hematologic Malignancies Testing Market (by Platforms), Thousand Units, 2021, 2025, and 2032
  • Figure 113: France Hematologic Malignancies Testing Market (by Product), Thousand Units, 2021, 2025, and 2032
  • Figure 114: France Hematologic Malignancies Testing Market (by End User), Thousand Units, 2021, 2025, and 2032
  • Figure 115: U.K. Hematologic Malignancies Testing Market, $Million, 2021-2032
  • Figure 116: U.K. Hematologic Malignancies Testing Market, Thousand Units, 2021-2032
  • Figure 117: U.K. Hematologic Malignancies Testing Market (by Platform), $Million, 2021-2032
  • Figure 118: U.K. Hematologic Malignancies Testing Market (by Platforms), Thousand Units, 2021, 2025, and 2032
  • Figure 119: U.K. Hematologic Malignancies Testing Market (by Product), Thousand Units, 2021, 2025, and 2032
  • Figure 120: U.K. Hematologic Malignancies Testing Market (by End User), Thousand Units, 2021, 2025, and 2032
  • Figure 121: Italy Hematologic Malignancies Testing Market, $Million, 2021-2032
  • Figure 122: Italy Hematologic Malignancies Testing Market, Thousand Units, 2021-2032
  • Figure 123: Italy Hematologic Malignancies Testing Market (by Platform), $Million, 2021-2032
  • Figure 124: Italy Hematologic Malignancies Testing Market (by Platforms), Thousand Units, 2021, 2025, and 2032
  • Figure 125: Italy Hematologic Malignancies Testing Market (by Product), Thousand Units, 2021, 2025, and 2032
  • Figure 126: U.S. Hematologic Malignancies Testing Market (by End User), Thousand Units, 2021, 2025, and 2032
  • Figure 127: Spain Hematologic Malignancies Testing Market, $Million, 2021-2032
  • Figure 128: Spain Hematologic Malignancies Testing Market, Thousand Units, 2021-2032
  • Figure 129: Spain Hematologic Malignancies Testing Market (by Platform), $Million, 2021-2032
  • Figure 130: Spain Hematologic Malignancies Testing Market (by Platforms), Thousand Units, 2021, 2025, and 2032
  • Figure 131: Spain Hematologic Malignancies Testing Market (by Product), Thousand Units, 2021, 2025, and 2032
  • Figure 132: Spain Hematologic Malignancies Testing Market (by End User), Thousand Units, 2021, 2025, and 2032
  • Figure 133: Denmark Hematologic Malignancies Testing Market, $Million, 2021-2032
  • Figure 134: Denmark Hematologic Malignancies Testing Market, Thousand Units, 2021-2032
  • Figure 135: Denmark Hematologic Malignancies Testing Market (by Platform), $Million, 2021-2032
  • Figure 136: Denmark Hematologic Malignancies Testing Market (by Platforms), Thousand Units, 2021, 2025, and 2032
  • Figure 137: Denmark Hematologic Malignancies Testing Market (by Product), Thousand Units, 2021, 2025, and 2032
  • Figure 138: Denmark Hematologic Malignancies Testing Market (by End User), Thousand Units, 2021, 2025, and 2032
  • Figure 139: Rest-of-Europe Hematologic Malignancies Testing Market, $Million, 2021-2032
  • Figure 140: Rest-of-Europe Hematologic Malignancies Testing Market, Thousand Units, 2021-2032
  • Figure 141: Rest-of-Europe Hematologic Malignancies Testing Market (by Platform), $Million, 2021-2032
  • Figure 142: Rest-of-Europe Hematologic Malignancies Testing Market (by Platforms), Thousand Units, 2021, 2025, and 2032
  • Figure 143: Rest-of Europe Hematologic Malignancies Testing Market (by Product), Thousand Units, 2021, 2025, and 2032
  • Figure 144: Rest-of-Europe Hematologic Malignancies Testing Market (by End User), Thousand Units, 2021, 2025, and 2032
  • Figure 145: Asia-Pacific Hematologic Malignancies Testing Market, $Million, 2021-2032
  • Figure 146: Asia-Pacific Hematologic Malignancies Testing Market (by Country), $Million, 2021-2032
  • Figure 147: Asia-Pacific: Market Dynamics
  • Figure 148: Asia-Pacific Hematologic Malignancies Testing Market, Thousand Units, 2021-2032
  • Figure 149: China Hematologic Malignancies Testing Market, $Million, 2021-2032
  • Figure 150: China Hematologic Malignancies Testing Market, Thousand Units, 2021-2032
  • Figure 151: China Hematologic Malignancies Testing Market (by Platform), $Million, 2021-2032
  • Figure 152: China Hematologic Malignancies Testing Market (by Platforms), Thousand Units, 2021, 2025, and 2032
  • Figure 153: China Hematologic Malignancies Testing Market (by Product), Thousand Units, 2021, 2025, and 2032
  • Figure 154: China Hematologic Malignancies Testing Market (by End User), Thousand Units, 2021, 2025, and 2032
  • Figure 155: Japan Hematologic Malignancies Testing Market, $Million, 2021-2032
  • Figure 156: Japan Hematologic Malignancies Testing Market, Thousand Units, 2021-2032
  • Figure 157: Japan Hematologic Malignancies Testing Market (by Platform), $Million, 2021-2032
  • Figure 158: Japan Hematologic Malignancies Testing Market (by Platforms), Thousand Units, 2021, 2025, and 2032
  • Figure 159: Japan Hematologic Malignancies Testing Market (by Product), Thousand Units, 2021, 2025, and 2032
  • Figure 160: Japan Hematologic Malignancies Testing Market (by End User), Thousand Units, 2021, 2025, and 2032
  • Figure 161: India Hematologic Malignancies Testing Market, $Million, 2021-2032
  • Figure 162: India Hematologic Malignancies Testing Market, Thousand Units, 2021-2032
  • Figure 163: India Hematologic Malignancies Testing Market (by Platform), $Million, 2021-2032
  • Figure 164: India Hematologic Malignancies Testing Market (by Platforms), Thousand Units, 2021, 2025, and 2032
  • Figure 165: India Hematologic Malignancies Testing Market (by Product), Thousand Units, 2021, 2025, and 2032
  • Figure 166: India Hematologic Malignancies Testing Market (by End User), Thousand Units, 2021, 2025, and 2032
  • Figure 167: South Korea Hematologic Malignancies Testing Market, $Million, 2021-2032
  • Figure 168: South Korea Hematologic Malignancies Testing Market, Thousand Units, 2021-2032
  • Figure 169: South Korea Hematologic Malignancies Testing Market (by Platform), $Million, 2021-2032
  • Figure 170: South Korea Hematologic Malignancies Testing Market (by Platforms), Thousand Units, 2021, 2025, and 2032
  • Figure 171: South Korea Hematologic Malignancies Testing Market (by Product), Thousand Units, 2021, 2025, and 2032
  • Figure 172: South Korea Hematologic Malignancies Testing Market (by End User), Thousand Units, 2021, 2025, and 2032
  • Figure 173: Australia Hematologic Malignancies Testing Market, $Million, 2021-2032
  • Figure 174: Number of Death in Australia by Leukemia (2012-2017)
  • Figure 175: Australia Hematologic Malignancies Testing Market, Thousand Units, 2021-2032
  • Figure 176: Australia Hematologic Malignancies Testing Market (by Platform), $Million, 2021-2032
  • Figure 177: Australia Hematologic Malignancies Testing Market (by Platform), Thousand Units, 2021, 2025, and 2032
  • Figure 178: Australia Hematologic Malignancies Testing Market (by Product), Thousand Units, 2021, 2025, and 2032
  • Figure 179: Australia Hematologic Malignancies Testing Market (by End User), Thousand Units, 2021, 2025, and 2032
  • Figure 180: Singapore Hematologic Malignancies Testing Market, $Million, 2021-2032
  • Figure 181: Singapore Hematologic Malignancies Testing Market, Thousand Units, 2021-2032
  • Figure 182: Singapore Hematologic Malignancies Testing Market (by Platform), $Million, 2021-2032
  • Figure 183: Singapore Hematologic Malignancies Testing Market (by Platform), Thousand Units, 2021, 2025, and 2032
  • Figure 184: Singapore Hematologic Malignancies Testing Market (by Product), Thousand Units, 2021, 2025, and 2032
  • Figure 185: Singapore Hematologic Malignancies Testing Market (by End User), Thousand Units, 2021, 2025, and 2032
  • Figure 186: Rest-of-Asia-Pacific Hematologic Malignancies Testing Market, $Million, 2021-2032
  • Figure 187: Rest-of-Asia-Pacific Hematologic Malignancies Testing Market, Thousand Units, 2021-2032
  • Figure 188: Rest-of-Asia-Pacific Hematologic Malignancies Testing Market (by Platform), $Million, 2021-2032
  • Figure 189: Rest-of-Asia-Pacific Hematologic Malignancies Testing Market (by Platforms), Thousand Units, 2021, 2025, and 2032
  • Figure 190: Rest-of-Asia-Pacific Hematologic Malignancies Testing Market (by Product), Thousand Units, 2021, 2025, and 2032
  • Figure 191: Rest-of-Asia-Pacific Hematologic Malignancies Testing Market (by End User), Thousand Units, 2021, 2025, and 2032
  • Figure 192: Latin America Hematologic Malignancies Testing Market, $Million, 2021-2032
  • Figure 193: Latin America Hematologic Malignancies Testing Market (by Country), $Million, 2021-2032
  • Figure 194: Latin America: Market Dynamics
  • Figure 195: Latin America Hematologic Malignancies Testing Market, Thousand Units, 2021-2032
  • Figure 196: Brazil Hematologic Malignancies Testing Market, $Million, 2021-2032
  • Figure 197: Brazil Hematologic Malignancies Testing Market, Thousand Units, 2021-2032
  • Figure 198: Brazil Hematologic Malignancies Testing Market (by Platform), $Million, 2021-2032
  • Figure 199: Brazil Hematologic Malignancies Testing Market (by Platform), Thousand Units, 2021, 2025, and 2032
  • Figure 200: Brazil Hematologic Malignancies Testing Market (by Product), Thousand Units, 2021, 2025, and 2032
  • Figure 201: Brazil Hematologic Malignancies Testing Market (by End User), Thousand Units, 2021, 2025, and 2032
  • Figure 202: Mexico Hematologic Malignancies Testing Market, $Million, 2021-2032
  • Figure 203: Mexico Hematologic Malignancies Testing Market, Thousand Units, 2021-2032
  • Figure 204: Mexico Hematologic Malignancies Testing Market (by Platform), $Million, 2021-2032
  • Figure 205: Mexico Hematologic Malignancies Testing Market (by Platforms), Thousand Units, 2021, 2025, and 2032
  • Figure 206: Mexico Hematologic Malignancies Testing Market (by Product), Thousand Units, 2021, 2025, and 2032
  • Figure 207: Mexico Hematologic Malignancies Testing Market (by End User), Thousand Units, 2021, 2025, and 2032
  • Figure 208: Rest-of-Latin America Hematologic Malignancies Testing Market, $Million, 2021-2032
  • Figure 209: Rest-of-Latin America Hematologic Malignancies Testing Market, Thousand Units, 2021-2032
  • Figure 210: Rest-of-Latin America Hematologic Malignancies Testing Market (by Platform), $Million, 2021-2032
  • Figure 211: Rest-of-Latin America Hematologic Malignancies Testing Market (by Platforms), Thousand Units, 2021, 2025, and 2032
  • Figure 212: Rest-of-Latin America Hematologic Malignancies Testing Market (by Product), Thousand Units, 2021, 2025, and 2032
  • Figure 213: Rest-of-Latin America Hematologic Malignancies Testing Market (by End User), Thousand Units, 2021, 2025, and 2032
  • Figure 214: Rest-of-the-World Hematologic Malignancies Testing Market, $Million, 2021-2032
  • Figure 215: Rest-of-the-World Hematologic Malignancies Testing Market, Thousand Units, 2021-2032
  • Figure 216: Total Number of Companies Profiled
  • Figure 217: Abbott.: Overall Product Portfolio
  • Figure 218: Abbott.: Overall Financials, $Million, 2019-2021
  • Figure 219: Abbott.: Revenue (by Segment), $Million, 2019-2021
  • Figure 220: Abbott.: Revenue (by Region), $Million, 2019-2021
  • Figure 221: Abbott.: R&D Expenditure, $Million, 2019-2021
  • Figure 222: ASURAGEN, INC.: Overall Product Portfolio
  • Figure 223: Adaptive Biotechnologies: Overall Product Portfolio
  • Figure 224: Adaptive Biotechnologies: Overall Financials, $Million, 2019-2021
  • Figure 225: Adaptive Biotechnologies: Revenue (by Segment), $Million, 2019-2021
  • Figure 226: Adaptive Biotechnologies: R&D Expenditure, $Million, 2019-2021
  • Figure 227: ARUP Laboratories: Overall Product Portfolio
  • Figure 228: Bio-Rad Laboratories, Inc.: Overall Product Portfolio
  • Figure 229: Bio-Rad Laboratories, Inc.: Overall Financials, $Million, 2019-2021
  • Figure 230: Bio-Rad Laboratories, Inc.: Revenue (by Segment), $Million, 2019-2021
  • Figure 231: Bio-Rad Laboratories, Inc.: Revenue (by Region), $Million, 2019-2021
  • Figure 232: Bio-Rad Laboratories, Inc.: R&D Expenditure, $Million, 2019-2021
  • Figure 233: F. Hoffmann-La Roche Ltd: Overall Product Portfolio
  • Figure 234: F. Hoffmann-La Roche Ltd: Overall Financials, $Million, 2019-2021
  • Figure 235: F. Hoffmann-La Roche Ltd: Revenue (by Segment), $Million, 2019-2021
  • Figure 236: F. Hoffmann-La Roche Ltd: Revenue (by Region), $Million, 2019-2021
  • Figure 237: F. Hoffmann-La Roche Ltd: R&D Expenditure, $Million, 2019-2021
  • Figure 238: Illumina, Inc.: Overall Product Portfolio
  • Figure 239: Illumina, Inc.: Overall Financials, $Million, 2019-2021
  • Figure 240: Illumina, Inc.: Revenue (by Segment), $Million, 2019-2021
  • Figure 241: Illumina, Inc.: Revenue (by Region), $Million, 2019-2021
  • Figure 242: Illumina, Inc.: R&D Expenditure, $Million, 2019-2021
  • Figure 243: ICON plc: Overall Product Portfolio
  • Figure 244: ICON plc: Overall Financials, $Million, 2019-2021
  • Figure 245: ICON plc: Revenue (by Region), $Million, 2019-2021
  • Figure 246: Invivoscribe, Inc.: Overall Product Portfolio
  • Figure 247: Invitae Corporation.: Overall Product Portfolio
  • Figure 248: Invitae Corporation.: Overall Financials, $Million, 2019-2021
  • Figure 249: Invitae Corporation.: Revenue (by Segment), $Million, 2019-2021
  • Figure 250: Invitae Corporation.: Revenue (by Region), $Million, 2019-2021
  • Figure 251: Invitae Corporation.: R&D Expenditure, $Million, 2019-2021
  • Figure 252: Laboratory Corporation of America Holdings: Overall Product Portfolio
  • Figure 253: Laboratory Corporation of America Holdings: Overall Financials, $Million, 2019-2021
  • Figure 254: Laboratory Corporation of America Holdings: Revenue (by Segment), $Million, 2019-2021
  • Figure 255: Laboratory Corporation of America Holdings: Revenue (by Region), $Million, 2019-2021
  • Figure 256: NeoGenomics Laboratories: Overall Product Portfolio
  • Figure 257: NeoGenomics Laboratories: Overall Financials, $Million, 2019-2021
  • Figure 258: NeoGenomics Laboratories: Revenue (by Segment), $Million, 2019-2021
  • Figure 259: NeoGenomics Laboratories: R&D Expenditure, $Million, 2019-2021
  • Figure 260: OHSU's Knight Diagnostic Laboratories: Overall Product Portfolio
  • Figure 261: Precipio: Overall Product Portfolio
  • Figure 262: Precipio: Overall Financials, $Million, 2019-2021
  • Figure 263: Precipio: Revenue (by Segment), $Million, 2019-2021
  • Figure 264: QIAGEN N.V.: Overall Product Portfolio
  • Figure 265: QIAGEN N.V.: Overall Financials, $Million, 2019-2021
  • Figure 266: QIAGEN N.V.: Revenue (by Segment), $Million, 2019-2021
  • Figure 267: QIAGEN N.V.: Revenue (by Region), $Million, 2019-2021
  • Figure 268: QIAGEN N.V.: R&D Expenditure, $Million, 2019-2021
  • Figure 269: Quest Diagnostics: Overall Product Portfolio
  • Figure 270: Quest Diagnostics: Overall Financials, $Million, 2019-2021
  • Figure 271: Quest Diagnostics: Revenue (by Segment), $Million, 2019-2021
  • Figure 272: Sysmex Corporation: Overall Product Portfolio
  • Figure 273: Sysmex Corporation: Overall Financials, $Million, 2018-2020
  • Figure 274: Sysmex Corporation: Revenue (by Segment), $Million, 2018-2020
  • Figure 275: Sysmex Corporation: Revenue (by Region), $Million, 2018-2020
  • Figure 276: Sysmex Corporation: R&D Expenditure, $Million, 2018-2020

List of Tables

  • Table 1: Diagnostic Tests for Hematologic Malignancies
  • Table 2: Likert Scale
  • Table 3: Impact Analysis of Market Drivers
  • Table 4: Impact Analysis of Market Restraints
  • Table 5: Registration Criteria for IVDs as per the CFDA
  • Table 6: Effect of COVID-19 on Cancer Care Throughout the World
  • Table 7: Companies Offering Gene Panels
  • Table 8: Companies Offering Services
  • Table 9: NGS-Based Products
  • Table 10: PCR-Based Products
  • Table 11: Companies Offering FISH-Based Products
  • Table 12: Companies Offering IHC-Based Products
  • Table 13: Company Offering Flow Cytometry-Based Product
  • Table 14: Estimated Cases of Leukemia, by Gender, 2021
  • Table 15: Companies Offering Leukemia Testing Products
  • Table 16: Estimated Cases of Lymphoma, by Gender, 2021
  • Table 17: Companies Offering Lymphoma Testing Products
  • Table 18: Estimated Cases of Myeloma, by Gender, 2021
  • Table 19: Companies Offering Multiple Myeloma Products
目次
Product Code: BHP0771SB

“Global Hematologic Malignancies Testing Market to Reach $11,680.1 Million by 2032.”

Hematologic Malignancies Testing Market: Industry Overview

The global hematologic malignancies testing market is projected to reach $11,680.1 million by 2032, growing from $2,606.5 million in 2021, at a CAGR of 14.23% during the forecast period 2022-2032. The global market for hematologic malignancies testing has grown significantly, owing to the rising demand for numerous biomarker-based molecular diagnostics. The advancements have aided in enhancing the quality of life and decreasing treatment costs and time, driving the overall growth of the healthcare diagnostics market. Furthermore, the worldwide hematologic malignancies testing market is being driven by rising awareness and adoption of the precision diagnostic technique in both developed and developing countries.

Market Lifecycle Stage

Hematologic malignancies are a type of cancer that starts in blood-forming tissue, such as the bone marrow or immune system cells. With an enhanced genomic review of cancer and developments in molecular diagnostic technology, genetic characterization has become increasingly important in the clinical evaluation of practically every kind of hematologic malignancy. In economically developed countries, hematological malignancies (blood cancers) are the fifth most prevalent cancer kind. They're generally divided into three groups based on whether cancer starts in the blood (leukemia), lymph nodes (Hodgkin's lymphoma and non-Hodgkin's lymphoma), or bone (osteosarcomas and myelomas). The global hematologic malignancies testing market is undergoing a significant change about the advancements that have already taken place and are currently invading the market space. Additionally, with the emergence of advanced diagnostic technologies, there is immense potential for emerging submarkets such as the nucleic acid extraction market to continue fueling the overall hematologic malignancies testing market. Further, with highly opportunistic trends coming into play with the rapid incorporation of hematologic malignancies testing in the management of cancer in healthcare settings, there is immense potential for growth in this market.

Impact

  • The presence of major service providers of hematologic malignancies testing products has a significant impact on the market. For instance, In South Bend, Indiana, Laboratory Corporation of America Holdings opened a new diagnostics laboratory, allowing the company to expand service levels and products to patients and doctors in the area.
  • Companies such as F. Hoffmann-La Roche Ltd released the AVENIO Tumor Tissue CGP Kit, which complements Roche and Foundation Medicine's current CGP offering and enables laboratories to extend their oncology research in-house. In the end, a future version of the kit could result in more resources for clinicians to employ in cancer diagnosis and therapy. The presence of such products has a positive impact on market growth.

Impact of COVID-19

In the U.S. and around the world, cancer is the leading cause of death. Cancer testing is an important preventive measure that can lower the incidence and death of cancer. While cancer prevention and screening are important for individual and societal health, the cancer market is undergoing significant changes because of the COVID-19 epidemic. COVID-19-related disruptions have impacted nearly every area of cancer control and prevention infrastructure, which includes canceled cancer diagnostic tests, postponed elective surgeries, deconstructed therapy regimens, and unemployed healthcare providers. Patients, healthcare providers, and healthcare systems may all suffer because of the disruption in cancer screening tests.

Cancer screening is crucial for early cancer detection; however, COVID-19 has slowed the cancer screening infrastructure greatly. Many cancer organizations have championed the idea of suspending cancer screening services to patients to alter the provision of healthcare resources. Following the declaration of a national emergency in the U.S. on March 13, 2020, organizations such as the American Cancer Society advised people to put their cancer screening plans on hold until further notice during the COVID-19 outbreak. Cancer screening services have been severely disrupted because of this proposal, as well as other contextual circumstances (e.g., social exclusion measures).

Successful cancer screening is frequently achieved through synergistic collaborations among patients, healthcare providers, and health systems. Furthermore, because there is no information on the virus' origins and no effective vaccination or curative therapy, both patients and healthcare providers share the same unknowns and doubts about COVID-19. Health systems, whose financial prospects may be challenged, are also affected by this uncertainty. It is expected that, with the restrictions gradually being removed from several regions around the world, coupled with research activities resuming normalcy, the market will face a low impact on the annual revenue generation.

Market Segmentation

Segmentation 1: by Platform

  • Polymerase Chain Reaction (PCR)
  • Next-Generation Sequencing (NGS)
  • Fluorescence In-Situ Hybridization (FISH)
  • Flow Cytometry
  • Immunohistochemistry (IHC)
  • Other Platforms

The hematologic malignancies testing market (by platform) was dominated by the polymerase chain reaction (PCR) segment in 2021. This was due to an increasing number of PCR kits that providers offer to their end users.

Segmentation 2: by Disease

  • Leukemia
  • Lymphoma
  • Multiple Myeloma
  • Myeloproliferative Neoplasm
  • Myelodysplastic Syndrome

In 2021, leukemia disease dominated the hematologic malignancies testing market due to an increasing number of patients suffering from cancer. According to the data published by the World Health Organization, cancer is a leading cause of death, with nearly 10 million deaths reported in 2020.

Segmentation 3: by Product

  • Kits
  • Services

The hematologic malignancies testing market (by product) was dominated by the services segment in 2021. This growth was attributed to academic research and industry collaboration. Moreover, the technological advancement in RUO products is boosting the growth of the hematologic malignancies testing market.

Segmentation 4: by End User

  • Specialty Clinics and Hospitals
  • Diagnostic Laboratories
  • Reference Laboratories
  • Research Institutions

In 2021, the hematologic malignancies testing market (by end user) was dominated by the specialty clinics, and hospitals segment as these clinics have all the necessary information and topic competence to perform disease diagnostic tests.

Segmentation 5: by Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Rest-of-the-World

North America generated the highest revenue of $1,491.7 million in 2021, which is attributed to the R&D advancements in the field of oncology testing and the presence of dominating players operating in the hematologic malignancies testing market.

Recent Developments in Hematologic Malignancies Testing Market

  • In August 2021, GRAIL, a healthcare business focused on life-saving early identification of various malignancies, was acquired by Illumina, Inc. The Galleri blood test developed by GRAIL diagnoses various malignancies before they become symptomatic. GRAIL's acquisition by Illumina has accelerated access to and acceptance of the life-saving test around the world.
  • In October 2021, F. Hoffmann-La Roche Ltd released the AVENIO Tumor Tissue CGP Kit, enabling laboratories to extend their oncology research in-house.
  • In January 2021, F. Hoffmann-La Roche Ltd partnered with Sysmex Corporation to evolve and provide hematology testing advances to laboratories around the world. The firms have renewed their long-standing distribution, sales, and services (DSS) agreement, allowing Roche to continue to distribute Sysmex hematology goods, including instruments and reagents.

Demand - Drivers and Limitations

Following are the demand drivers for the hematologic malignancies testing market:

  • Increasing Key Player Initiatives
  • Growing Funding in the Market for Hematologic Malignancies Testing

The market is expected to face some limitations too due to the following challenges:

  • Lack of Qualified Professionals
  • Issues Concerning the Analytical Validity of Cancer Genetic Testing

How Can This Report Add Value to an Organization?

  • Product/Innovation Strategy: The product segment helps the reader understand the types of products, i.e., kits and services. These ecosystems are the primary focus of the study as these are the target of market players in terms of revenue generation. Moreover, the study provides the reader with a detailed understanding of the different diseases such as leukemia, lymphoma, multiple myeloma, myeloproliferative neoplasm, and myelodysplastic syndrome.
  • Growth/Marketing Strategy: The hematologic malignancies testing market has been dominated significantly by companies such as QIAGEN N.V., Abbott., Bio-Rad Laboratories, Inc., and F. Hoffmann-La Roche Ltd due to their expansive portfolio and strong regional presence across the world. Many companies such as Precipio, Sysmex Corporation, Illumina, Inc., ARUP Laboratories, and Adaptive Biotechnologies lie in the low growth and low market share segment. The low market share of these companies is primarily due to limited products with respect to the hematologic malignancies testing market in comparison to other segments of these companies. Also, the lack of synergistic activities with respect to the market is responsible for the low growth of these companies.
  • Competitive Strategy: Key players in the hematologic malignancies testing market analyzed and profiled in the study has involved the oncology application-based product manufacturers that provide hematologic malignancies testing kits and services. Moreover, a detailed competitive benchmarking of the players operating in the hematologic malignancies testing market has been done to help the reader understand how players stack against each other, presenting a clear market landscape. Additionally, comprehensive competitive strategies such as partnerships, agreements, and collaborations will aid the reader in understanding the untapped revenue pockets in the market.

Key Market Players and Competition Synopsis

The companies that are profiled have been selected based on inputs gathered from primary experts and analyzing company coverage, product portfolio, and market penetration.

Some prominent names established in this market are:

    • Abbott.
    • ASURAGEN, INC.
    • Adaptive Biotechnologies
    • ARUP Laboratories
    • Bio-Rad Laboratories, Inc.
    • F. Hoffmann-La Roche Ltd
    • Illumina, Inc.
    • ICON plc
    • Invivoscribe, Inc.
    • Invitae Corporation.
    • Laboratory Corporation of America Holdings
    • NeoGenomics Laboratories
    • OHSU's Knight Diagnostic Laboratories
    • Precipio
    • QIAGEN N.V.
    • Quest Diagnostics
    • Sysmex Corporation

Table of Contents

1 Market

  • 1.1 Product Definition
    • 1.1.1 Inclusion and Exclusion
  • 1.2 Market Scope
    • 1.2.1 Scope of the Study
    • 1.2.2 Key Questions Answered in the Report
  • 1.3 Market Overview
    • 1.3.1 Introduction
    • 1.3.2 Types of Hematologic Malignancies Diagnostic Tests
    • 1.3.3 Market Footprint and Growth Potential

2 Market Dynamics

  • 2.1 Overview
  • 2.2 Impact Analysis
  • 2.3 Market Drivers
    • 2.3.1 Rising Incidence in Hematologic Malignancies
      • 2.3.1.1 New Cases
      • 2.3.1.2 Deaths
    • 2.3.2 Increasing Key Player Initiatives
    • 2.3.3 Growing Funding in the Market for Hematologic Malignancies Testing
  • 2.4 Market Restraints
    • 2.4.1 Lack of Qualified Professionals
    • 2.4.2 Issues Concerning the Analytical Validity of Cancer Genetic Testing
  • 2.5 Market Opportunities
    • 2.5.1 Increasing Research and Development Activities
    • 2.5.2 Technological Advancements in the Field of Hematologic Malignancies Testing
  • 2.6 Industry Analysis
    • 2.6.1 Regulatory Framework
    • 2.6.2 Regulatory Framework in the U.S.
    • 2.6.3 Regulatory Framework in Europe
    • 2.6.4 Regulatory Framework in Asia-Pacific
      • 2.6.4.1 Japan
      • 2.6.4.2 China
  • 2.7 COVID-19's Impact on Cancer Diagnostic Market
    • 2.7.1 Disruption in Global Hematologic Malignancies Testing Market Due to COVID-19
    • 2.7.2 Effect of COVID-19 on Cancer Medicine and Science
    • 2.7.3 Effect on Workforce and Research Funding
    • 2.7.4 Effect on Cancer Screening
    • 2.7.5 Future of Cancer Beyond COVID-19 in Medicine and Science
      • 2.7.5.1 Implementation of Telemedicine
  • 2.8 Supply Chain Analysis
    • 2.8.1 Key Entities in Supply Chain
  • 2.9 Pricing Analysis
    • 2.9.1 Pricing Analysis By Platform Testing
  • 2.1 Comparative Analysis of Hematologic Malignancies Test by Different Parameters

3 Competitive Landscape

  • 3.1 Overview
  • 3.2 Synergistic Activities
  • 3.3 Product Launches
  • 3.4 Product Approvals
  • 3.5 Mergers and Acquisitions
  • 3.6 Other Business Activities
  • 3.7 Market Share Analysis (by Company), 2020 and 2021
  • 3.8 Growth-Share Analysis (by Platform)

4 Products

  • 4.1 Overview
    • 4.1.1 Kits
      • 4.1.1.1 Gene Panels
      • 4.1.1.2 Molecular Clonality Testing
      • 4.1.1.3 Translocation Testing
      • 4.1.1.4 Mutation Testing
      • 4.1.1.5 Minimal Residual Disease (MRD) Testing
    • 4.1.2 Services

5 Platform

  • 5.1 Overview
    • 5.1.1 Next-Generation Sequencing (NGS)
    • 5.1.2 Polymerase Chain Reaction (PCR)
    • 5.1.3 Fluorescence In-Situ Hybridization (FISH)
    • 5.1.4 Immunohistochemistry (IHC)
    • 5.1.5 Flow Cytometry
    • 5.1.6 Other Platforms
      • 5.1.6.1 Cytogenetic Testing
      • 5.1.6.2 Microarray

6 Diseases

  • 6.1 Overview
  • 6.2 Leukemia
  • 6.3 Lymphoma
  • 6.4 Multiple Myeloma
  • 6.5 Myeloproliferative Neoplasms
  • 6.6 Myelodysplastic Syndromes

7 End User

  • 7.1 Overview
  • 7.2 Specialty Clinics and Hospitals
  • 7.3 Diagnostic Laboratories
  • 7.4 Reference Laboratories
  • 7.5 Research Institutions

8 Region

  • 8.1 Overview
  • 8.2 North America
    • 8.2.1 U.S.
    • 8.2.2 Canada
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 France
    • 8.3.3 U.K.
    • 8.3.4 Italy
    • 8.3.5 Spain
    • 8.3.6 Denmark
    • 8.3.7 Rest-of-Europe
  • 8.4 Asia-Pacific
    • 8.4.1 China
    • 8.4.2 Japan
    • 8.4.3 India
    • 8.4.4 South Korea
    • 8.4.5 Australia
    • 8.4.6 Singapore
    • 8.4.7 Rest-of-Asia-Pacific
  • 8.5 Latin America
    • 8.5.1 Brazil
    • 8.5.2 Mexico
    • 8.5.3 Rest-of-Latin America
  • 8.6 Rest-of-the-World

9 Market - Company Profiles

  • 9.1 Overview
  • 9.2 Abbott.
    • 9.2.1 Company Overview
    • 9.2.2 Role of Abbott. in the Global Hematologic Malignancies Testing Market
    • 9.2.3 Key Competitors of the Company
    • 9.2.4 Key Customers of the Company
    • 9.2.5 Corporate Strategies
    • 9.2.6 Financials
    • 9.2.7 Key Insights about the Financial Health of the Company
    • 9.2.8 Analyst Perspectives
  • 9.3 ASURAGEN, INC.
    • 9.3.1 Company Overview
    • 9.3.2 Role of ASURAGEN, INC. in the Global Hematologic Malignancies Testing Market
    • 9.3.3 Key Competitors of the Company
    • 9.3.4 Key Customers of the Company
    • 9.3.5 Analyst Perspectives
  • 9.4 Adaptive Biotechnologies
    • 9.4.1 Company Overview
    • 9.4.2 Role of Adaptive Biotechnologies in the Global Hematologic Malignancies Testing Market
    • 9.4.3 Key Competitors of the Company
    • 9.4.4 Key Customers of the Company
    • 9.4.5 Corporate Strategies
    • 9.4.6 Financials
    • 9.4.7 Key Insights about the Financial Health of the Company
    • 9.4.8 Analyst Perspectives
  • 9.5 ARUP Laboratories
    • 9.5.1 Company Overview
    • 9.5.2 Role of ARUP Laboratories in the Global Hematologic Malignancies Testing Market
    • 9.5.3 Key Competitors of the Company
    • 9.5.4 Key Customers of the Company
    • 9.5.5 Analyst Perspectives
  • 9.6 Bio-Rad Laboratories, Inc.
    • 9.6.1 Company Overview
    • 9.6.2 Role of Bio-Rad Laboratories, Inc. in the Global Hematologic Malignancies Testing Market
    • 9.6.3 Key Competitors of the Company
    • 9.6.4 Key Customers of the Company
    • 9.6.5 Financials
    • 9.6.6 Key Insights about the Financial Health of the Company
    • 9.6.7 Analyst Perspectives
  • 9.7 F. Hoffmann-La Roche Ltd
    • 9.7.1 Company Overview
    • 9.7.2 Role of F. Hoffmann-La Roche Ltd in the Global Hematologic Malignancies Testing Market
    • 9.7.3 Key Competitors of the Company
    • 9.7.4 Key Customers of the Company
    • 9.7.5 Corporate Strategies
    • 9.7.6 Business Strategies
    • 9.7.7 Financials
    • 9.7.8 Key Insights about the Financial Health of the Company
    • 9.7.9 Analyst Perspectives
  • 9.8 Illumina, Inc.
    • 9.8.1 Company Overview
    • 9.8.2 Role of Illumina, Inc. in the Global Hematology Malignancies Testing Market
    • 9.8.3 Key Competitors of the Company
    • 9.8.4 Key Customers of the Company
    • 9.8.5 Corporate Strategies
    • 9.8.6 Financials
    • 9.8.7 Key Insights about the Financial Health of the Company
    • 9.8.8 Analyst Perspectives
  • 9.9 ICON plc
    • 9.9.1 Company Overview
    • 9.9.2 Role of ICON plc in the Global Hematologic Malignancies Testing Market
    • 9.9.3 Key Competitors of the Company
    • 9.9.4 Key Customers of the Company
    • 9.9.5 Financials
    • 9.9.6 Analyst Perspectives
  • 9.1 Invivoscribe, Inc.
    • 9.10.1 Company Overview
    • 9.10.2 Role of Invivoscribe, Inc. in the Global Hematologic Malignancies Testing Market
    • 9.10.3 Key Competitors of the Company
    • 9.10.4 Key Customers of the Company
    • 9.10.5 Analyst Perspectives
  • 9.11 Invitae Corporation.
    • 9.11.1 Company Overview
    • 9.11.2 Role of Invitae Corporation. in the Global Hematologic Malignancies Testing Market
    • 9.11.3 Key Competitors of the Company
    • 9.11.4 Key Customers of the Company
    • 9.11.5 Corporate Strategies
    • 9.11.6 Financials
    • 9.11.7 Key Insights about the Financial Health of the Company
    • 9.11.8 Analyst Perspectives
  • 9.12 Laboratory Corporation of America Holdings
    • 9.12.1 Company Overview
    • 9.12.2 Role of Laboratory Corporation of America Holdings in the Global Hematologic Malignancies Testing Market
    • 9.12.3 Key Competitors of the Company
    • 9.12.4 Key Customers of the Company
    • 9.12.5 Corporate Strategies
    • 9.12.6 Financials
    • 9.12.7 Analyst Perspectives
  • 9.13 NeoGenomics Laboratories
    • 9.13.1 Company Overview
    • 9.13.2 Role of NeoGenomics Laboratories in the Global Hematologic Malignancies Testing Market
    • 9.13.3 Key Competitors of the Company
    • 9.13.4 Key Customers of the Company
    • 9.13.5 Financials
    • 9.13.6 Key Insights about the Financial Health of the Company
    • 9.13.7 Analyst Perspectives
  • 9.14 OHSU's Knight Diagnostic Laboratories
    • 9.14.1 Company Overview
    • 9.14.2 Role of OHSU's Knight Diagnostic Laboratories in the Global Hematologic Malignancies Testing Market
    • 9.14.3 Key Competitors of the Company
    • 9.14.4 Key Customers of the Company
    • 9.14.5 Analyst Perspectives
  • 9.15 Precipio
    • 9.15.1 Company Overview
    • 9.15.2 Role of Precipio in the Global Hematologic Malignancies Testing Market
    • 9.15.3 Key Competitors of the Company
    • 9.15.4 Key Customers of the Company
    • 9.15.5 Corporate Strategies
    • 9.15.6 Business Strategies
    • 9.15.7 Financials
    • 9.15.8 Analyst Perspectives
  • 9.16 QIAGEN N.V.
    • 9.16.1 Company Overview
    • 9.16.2 Role of QIAGEN N.V. in the Global Hematologic Malignancies Testing Market
    • 9.16.3 Key Competitors of the Company
    • 9.16.4 Key Customers of the Company
    • 9.16.5 Corporate Strategies
    • 9.16.6 Financials
    • 9.16.7 Key Insights about the Financial Health of the Company
    • 9.16.8 Analyst Perspectives
  • 9.17 Quest Diagnostics
    • 9.17.1 Company Overview
    • 9.17.2 Role of Quest Diagnostics in the Global Hematologic Malignancies Testing Market
    • 9.17.3 Key Competitors of the Company
    • 9.17.4 Key Customers of the Company
    • 9.17.5 Corporate Strategies
    • 9.17.6 Financials
    • 9.17.7 Analyst Perspectives
  • 9.18 Sysmex Corporation
    • 9.18.1 Company Overview
    • 9.18.2 Role of Sysmex Corporation in the Global Hematologic Malignancies Testing Market
    • 9.18.3 Key Competitors of the Company
    • 9.18.4 Key Customers of the Company
    • 9.18.5 Business Strategies
    • 9.18.6 Financials
    • 9.18.7 Key Insights about the Financial Health of the Company
    • 9.18.8 Analyst Perspectives